Company intelligence / Profile preview

NorthStar Medical Radioisotopes

Beloit, Wisconsin, United States

Ownership: Private
Development stage: Other

Overview

NorthStar Medical Radioisotopes has commercialized the FDA-approved RadioGenix System for production of non-uranium Mo-99 and Tc-99m for diagnostics, is the sole U.S. source for domestic Mo-99, and is producing copper-67 for clinical trials and scaling up production of actinium-225 and other therapeutic radioisotopes. Multiple isotope products are now in use clinically and new cleanrooms and manufacturing centers support clinical and commercial supply, including for partnered trials with Clarity Pharmaceuticals and others.[1][3][4][5][6][7]

Therapeutic areas: OncologyCardiovascular
Modalities: RadiopharmaceuticalRadiopharmaceutical CDMO services
Industry: Contract Manufacturing Organization

Partnerships

Clarity Pharmaceuticals

Beyond the preview

Go deeper on NorthStar Medical Radioisotopes.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NorthStar Medical Radioisotopes.

Explore the full profile